Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) - OpACIN-neo

Antoni van leeuwenhoek ziekenhuis0 个研究点目标入组 90 人开始时间: 2017年4月28日最近更新: 2017年12月11日

试验速览

暂无简介。

•Adults at least 18 years of age
•World Health Organization (WHO) Performance Status 0 or 1
•Cytologically and histologically confirmed resectable stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST 1.1), that can be biopsied, and no history of in-transit metastases within the last 6 months
•No other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years
•Patient willing to undergo triple tumor biopsies and extra blood withdrawal during screening and in case of relapse
•No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1
•No immunosuppressive medications within 6 months prior study inclusion
•Screening laboratory values must meet the following criteria: WBC = 2.0x109/L, Neutrophils =1.5x109/L, Platelets =100 x109/L, Hemoglobin =5.5 mmol/L, Creatinine =1.5x ULN, AST = 1.5 x ULN, ALT = 1.5 x ULN, Bilirubin =1.5 X ULN
•Normal LDH
•Women of childbearing potential (WOCBP) must use appropriate method(s) of contra-ception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 80
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Distantly metastasized melanoma
•History of in-transit metastases within the last 6 months
•No measurable lesion according to RECIST 1.1
•Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
•Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy
•Radiotherapy prior or post-surgery
•Patients will be excluded if they test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection
•Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
•Allergies and Adverse Drug Reaction
•- History of allergy to study drug components
•- History of severe hypersensitivity reaction to any monoclonal antibody
•Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events;
•Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
•Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion

发起方

Antoni van leeuwenhoek ziekenhuis